Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 3, 2009, Pages 397-404

  Yu, Yun Zhou ^a   Li, Na ^a   Wang, Shuang ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Botulinum neurotoxin; DNA vaccine; Electric pulses; Hc; Prime boost

Indexed keywords

BOTULINUM TOXIN A; DNA VACCINE; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRIC PULSE; ELECTRICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TARGETING; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON;

ANIMALS; ANTIBODIES; BOTULINUM TOXIN TYPE A; CLOSTRIDIUM BOTULINUM; DNA REPLICATION; FEMALE; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; VACCINES, DNA;

CLOSTRIDIUM BOTULINUM; MUS;

EID: 70350674187     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970802713470     Document Type: Article

References (30)

1. Turton, K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxtins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27, 552-558.
2. Schiavo, G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rew. 2000, 80, 717-766.
3. Byrne, M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82, 955-966.
4. Clayton, M.A., Clayton, J.M., Brown, D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 1995, 63, 2728-2742.
5. Byrne, M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 1998, 66, 4817-4822
6. Baldwin, M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 2005, 73, 6998-7005. (Pubitemid 41368869)
7. Middlebrook, J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv. Drug Deliv. Rev. 2005, 57, 1415-1423.
8. Clayton, J., Middlebrook J.L. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000, 18, 1855-1862.
9. Shyu, R.H., Shaio M.F., Tang, S.S., Shyu, H.F., Lee C.F., Tsai M.H., Smith J.E., Huang H.H., Wey J.J., Huang J.L., Chang H.H. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed. Sci. 2000, 7, 51-57.
10. Bennett, A.M., Perkins S.D., Holley J.L. DNA vaccination protects against botulinum neurotoxin type F. vaccine 2003, 21, 3110-3117.
11. Jathoul, A.P., Holley J.L., Garmory H.S. Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 2004, 22, 3942-3946.
12. Lee, J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith L.A., Smith J.F. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect. Immun. 2001, 69, 5709-5715.
13. Lee, J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S.L., Smith L.A., Smith J.F. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006, 24, 6886-6892.
14. Ulmer, J.B., Wahren B., Liu M.A. Gene-based vaccines: recent technical and clinical advances. Trends Mol. Med. 2006, 12, 216-222.
15. Dhama, K., Mahendran M., Gupta P.K., Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet. Res. Commun. 2008, 32, 341-356.
16. Yu, Y.Z., Zhang S.M., Sun Z.W., Wang S., Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A Vaccine 2007, 25, 8843-8850.
17. Yu, Y.Z., Sun Z.W., Li Na., Wang S., Wang R.L., Yu W.Y. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine. Immunopharmacol. Immunotoxicol. DOI: 10.1080/08923970802438433.
18. Lu, S., Wang, S., Grimes-Serrano, J.M. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 2008, 7, 175-191.
19. Trollet, C., Bloquel, C., Scherman, D., Bigey, P. Electrotransfer into skeletal muscle for protein expression.Curr. Gene Ther. 2006, 6, 561-578.
20. Cemazar, M., Sersa G. Electrotransfer of therapeutic molecules into tissues. Curr Opin. Mol. Ther. 2007, 9, 554-562.
21. Bloquel, C., Fabre E., Bureau M.F., Scherman D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J. Gene Med. 2004, 6, S11-S23.
22. Grønevik, E., von Steyern, F.V., Kalhovde J.M., Tjelle, T.E., Mathiesen, I. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J. Gene Med. 2005, 7, 218-227.
23. Otten, G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., O'Hagan D., Donnelly J., Widera G., Rabussay D., Lewis M.G., Barnett S., Ulmer J.B. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22, 2489-2493.
24. Otten, G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., Rabussay D., Barnett S., Ulmer J.B. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006, 24, 4503-4509.
25. Luckay, A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., Garcia-Hand D., Abdullah R., Braun R., Montefiori D.C., Rosati M., Felber B.K., Pavlakis G.N., Mathiesen I., Israel Z.R., Eldridge J.H., Egan M.A. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 2007, 81, 5257-5269.
26. Tjelle, T.E., Salte R., Mathiesen I., Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 2006, 24, 4667-4670.
27. Tjelle, T.E., Rabussay D., Ottensmeier C., Mathiesen I., Kjeken R. Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. Methods Mol. Biol. 2008, 423, 497-507.
28. Bhardwaj, D., Kushwaha A., Puri S.K., Herrera A., Singh N., Chauhan V.S. DNA prime-protein boost immunization in monkeys: efficacy of a novel construct containing functional domains of Plasmodium cynomolgi CS and TRAP. FEMS Immunol. Med. Microbiol. 2003, 39, 241-250.
29. Leung, L., Srivastava I.K., Kan E., Legg H., Sun Y., Greer C., Montefiori D.C., zur Megede J., Barnett S.W. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 2004, 18, 991-1001.
30. Li, Z., Zhang H., Fan X., Zhang Y., Huang J., Liu Q., Tjelle T.E., Mathiesen I., Kjeken R., Xiong S. DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 2006, 24, 4565-4568. (Pubitemid 44218844)